Results 291 to 300 of about 27,891 (313)
Some of the next articles are maybe not open access.
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
JAMA ophthalmologyImportance Recent studies have suggested an association between nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide usage. However, the limitations of those analyses warrant further investigation, given the frequency of use of these ...
Alan Y. Hsu +13 more
semanticscholar +1 more source
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Journal of the American Medical Association (JAMA)Importance Heart failure with preserved ejection fraction (HFpEF) is a major cause of hospitalization, often occurring in patients with cardiometabolic comorbidities such as obesity and type 2 diabetes.
Nils Krüger +7 more
semanticscholar +1 more source
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
New England Journal of MedicineBACKGROUND Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity.
Sean Wharton +8 more
semanticscholar +1 more source
Semaglutide: Double-edged Sword with Risks and Benefits
Archives of Internal Medicine ResearchType 2 Diabetes Mellitus therapy has evolved over the years to now include a new class of therapeutics, semaglutide. This article reviews the mechanism of action and formulation of semaglutide therapy, potential benefits, contraindications, adverse ...
Lekha Pillarisetti, Devendra K. Agrawal
semanticscholar +1 more source
Hepatology
This practice recommendation serves as an update to the 2023 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (3 ...
Meena B Bansal +5 more
semanticscholar +1 more source
This practice recommendation serves as an update to the 2023 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (3 ...
Meena B Bansal +5 more
semanticscholar +1 more source
Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.
Journal of the American Medical Association (JAMA)This study uses data from the US nationwide electronic health record–based Epic Cosmos Dataset to examine prescriptions for semaglutide and tirzepatide, focusing on differences across race, ethnicity, social vulnerability, and urbanicity and assess the
Chungsoo Kim +6 more
semanticscholar +1 more source